Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Chd-Ldl'

Chd-Ldl published presentations and documents on DocSlides.

CHDO 101 Community Housing Development Organization (CHDO) Roles
CHDO 101 Community Housing Development Organization (CHDO) Roles
by cheryl-pisano
“One of the newest figures to emerge on the wor...
The case for intensive lipid management:
The case for intensive lipid management:
by SillyGoose
The opportunities and issues for cardiologists. Pr...
D yslipidemia DR,DUAA HIASAT
D yslipidemia DR,DUAA HIASAT
by mackenzie
Objectives :.  Know the clinical terminology for ...
D yslipidemia Objectives :
D yslipidemia Objectives :
by arya
 Know the clinical terminology for . dyslipidemia...
Invasive test results CHD
Invasive test results CHD
by tremblay
Astraia-search CHD. Q-diagnoses CHD*. * CHD=struct...
Health impact and monetary costs of dietary salt reduction policies: the CHD Policy Model
Health impact and monetary costs of dietary salt reduction policies: the CHD Policy Model
by eliza
Andrew Moran MD, MPH. Department of Medicine,. Col...
Genetic Testing after Fetal Diagnosis of CHD
Genetic Testing after Fetal Diagnosis of CHD
by wilson
July 2020 Journal Club of the Fetal Heart Society....
CHDP Director/Deputy Director Training
CHDP Director/Deputy Director Training
by tawny-fly
Section IV. CHDP Program Eligibility. 1. 7/1/2010...
CHDO 401 Predevelopment – Assembling a Good Project
CHDO 401 Predevelopment – Assembling a Good Project
by trish-goza
Project Development Phases. Feasibility. Pre-Deve...
1 1 CHDP DIRECTOR/DEPUTY DIRECTOR TRAINING
1 1 CHDP DIRECTOR/DEPUTY DIRECTOR TRAINING
by stefany-barnette
SECTION XIII. 7/1/2010. 1. Local . Program Respon...
Coronary Heart Disease (CHD):
Coronary Heart Disease (CHD):
by yoshiko-marsland
A Disease of Affluence . Lesson Objectives. I und...
CHDP DIRECTOR/DEPUTY Director Training
CHDP DIRECTOR/DEPUTY Director Training
by marina-yarberry
Section IX. Annual Plan Development. 7/1/2010. 1....
CHDP Director/Deputy Director Training
CHDP Director/Deputy Director Training
by giovanna-bartolotta
Section IV. CHDP Program Eligibility. 1. 7/1/2010...
CHDP Director/Deputy Director Training
CHDP Director/Deputy Director Training
by danika-pritchard
Section III. EPSDT: A Comprehensive Child Health ...
CHDP Director/Deputy Director Training
CHDP Director/Deputy Director Training
by liane-varnes
Section VI. Provider Network. 7/1/2010. Eligibili...
Risk Factors for CHD-
Risk Factors for CHD-
by ellena-manuel
Indications for Fetal Echo Revisited. Amy Svenson...
1 Dr. Samuel Wainaina (
1 Dr. Samuel Wainaina (
by iris
D.Pharm. , . Bpharm. , MSc ). O. utl. i. ne. Intro...
Diabetic dyslipidemia : The pro-
Diabetic dyslipidemia : The pro-
by deborah
atherogenic. role of CETP and future use of CETP ...
A naturally randomized trial evaluating the potential clinical benefit of triglyceride lowering the
A naturally randomized trial evaluating the potential clinical benefit of triglyceride lowering the
by arya
Brian A. . Ference. MD, . MPhil. , . MSc. , John ...
Triglycerides and Risk for Atherothrombosis
Triglycerides and Risk for Atherothrombosis
by briana-ranney
Thomas Dayspring, MD, FACP. Clinical Assistant Pr...
Cholesterol Treatment Trialists’ (CTT) Collaboration
Cholesterol Treatment Trialists’ (CTT) Collaboration
by briana-ranney
Slide deck. CTT Collaboration: Background*. Histo...
DIABETES AND LIPID
DIABETES AND LIPID
by yoshiko-marsland
S-KHALILZADEH. Lipids are hydrophobic molecules t...
Residual risk: Is LDL target enough?
Residual risk: Is LDL target enough?
by candy
An interpretation of the continuous relationship b...
Lifestyle Tips to Lower Your LDL Cholesterol
Lifestyle Tips to Lower Your LDL Cholesterol
by dandy
Advice f rom the National Lipid Association Clini...
PCSK9 Inhibition: LDL Lowering
PCSK9 Inhibition: LDL Lowering
by SweetiePie
PCSK9 inhibitors. New option for dyslipidemia. Ali...
LDL-CHOLESTEROL Presented By
LDL-CHOLESTEROL Presented By
by williams
Assist.Lecturer. Aseel. . Ghassan. . Daoud. M.Sc...
LDL is causal of atherosclerosis
LDL is causal of atherosclerosis
by morgan
Evidence from . meta-analyses of . Mendelian. . r...
LDL Apheresis in Drug Resistant Nephrotic Syndrome
LDL Apheresis in Drug Resistant Nephrotic Syndrome
by obrien
Rodney D Gilbert. Patient JM. 14 year old girl, pr...
Is lower better? LDL targets and beyond.
Is lower better? LDL targets and beyond.
by olivia-moreira
Implications of the relationship between risk fac...
Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
by min-jolicoeur
NICE –CG 181 Continuum of CVD Risk and its trea...
Is lower better? LDL targets and beyond.
Is lower better? LDL targets and beyond.
by trish-goza
Implications of the relationship between risk fac...
Abnormalities of LDL metabolism
Abnormalities of LDL metabolism
by briana-ranney
Physiology, pathophysiology and treatments. Under...
Presentation of Congenital Heart Disease in the Neonate and the Young Child
Presentation of Congenital Heart Disease in the Neonate and the Young Child
by callen313
Different presentations of CHD in the neonate. Asy...
Graphing Logits Graphing Proportion Positive (Rates)
Graphing Logits Graphing Proportion Positive (Rates)
by walsh
data. chd2018_a(. keep. =. chd. age);. . set. ...
Outline of the ion test in 2013
Outline of the ion test in 2013
by josephine
Tadahisa TAMURA for Beam Testing Team. 2013.5.28. ...
Vitamin D and cardiovascular disease
Vitamin D and cardiovascular disease
by susan
Ian de Boer, MD, MS. Associate Professor of Medici...
Diet and health A balanced diet
Diet and health A balanced diet
by ariel
A balanced diet is based on the Eatwell Guide.. An...
a rogyakeralam.gov.in SHALABHAM-
a rogyakeralam.gov.in SHALABHAM-
by roberts
. COMPREHENSIVE NEWBORN SCREENING. PROGRAM IN KERA...
Statistical Shape Analysis in Congenital Heart Disease (CHD)
Statistical Shape Analysis in Congenital Heart Disease (CHD)
by hailey
Lasya Gaur, MD. Assistant Professor, Pediatric Car...
De-risking the development programs of CETP inhibitors after the
De-risking the development programs of CETP inhibitors after the
by scarlett
torcetrapib. failure: Endothelial function & ...